Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Market Size Estimates For The Adult Malignant Glioma Therapeutics Market?

In recent years, the market size for adult malignant glioma therapeutics has seen swift expansion. It is projected to rise from $2.25 billion in 2024 to $2.47 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The growth experienced in the past can be linked to factors such as higher incidence rates, initiatives for patient advocacy, and the adoption of personalized medicine approaches.

In the forthcoming years, the adult malignant glioma therapeutics market is anticipated to witness substantial growth, escalating to $3.56 billion in 2029, with a compound annual growth rate of 9.5%. The predicted growth within the forecast timeline can be ascribed to advancements in immunotherapy, targeted therapies, discovery of biomarkers, applications of liquid biopsy, and broadened access programs. Key trends projected during the forecast duration encompass patient-oriented drug development, expedited and innovative designation, progress in drug delivery systems, collaborative research engagements, and incorporation of artificial intelligence.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp

Which Industry Forces Are Driving The Adult Malignant Glioma Therapeutics Market Forward?

The increase in brain tumor cases is predicted to fuel the expansion of the adult malignant glioma therapeutics market. A brain tumor is characterized as an unusual tissue mass where the regulatory systems for normal cells seem to have no impact on the relentless cell growth and multiplication. Adult malignant glioma is a form of brain tumor consisting of cells that exhibit abnormal and uncontrollable growth. The treatment for adult malignant glioma entails a combination of surgery, radiation therapy, and chemotherapy. For example, the American Cancer Society, a nonprofit cancer advocacy organization based in the United States, reported that in 2023 the number of brain and nervous system cancer cases surged to 24,810, a 3.85% increase from 23,890 in 2020. Consequently, the rise in brain tumor cases is stimulating the growth of the adult malignant glioma therapeutics market.

How Is The Adult Malignant Glioma Therapeutics Market Organized By Different Segments?

The adult malignant glioma therapeuticsmarket covered in this report is segmented –

1) By Type Of Disease: Glioblastoma Multiforme; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma; Other Types

2) By Therapy: Chemotherapy; Targeted Therapy; Radiotherapy; Other Therapies

3) By End-User: Hospitals; Specialty Clinics; Cancer And Radiation Therapy Centers; Other End Users

Subsegments:

1) By Glioblastoma Multiforme: Standard Treatments; Experimental Therapies

2) By Anaplastic Astrocytoma: Chemotherapy Options; Targeted Therapies

3) By Anaplastic Oligodendroglioma: Radiation Therapy; Combination Therapies

4) By Anaplastic Oligoastrocytoma: Surgical Interventions; Adjuvant Therapies

5) By Other Types: Rare Gliomas; Emerging Therapies

What Key Trends Are Driving Growth In The Adult Malignant Glioma Therapeutics Market?

Companies leading the market for adult malignant glioma therapeutics are working on product innovation, including the creation of small molecule targeted degraders, to enhance customer service and efficacy. These targeted degraders use small molecules to promote the degradation of particular proteins, by directing attention to the protein of interest (POI) and an E3 ubiquitin ligase. One such company is Beactica Therapeutics AB, based in Sweden, which in February 2023 received the green light from the U.S. Food and Drug Administration (FDA) for the use of BEA-17 in glioblastoma (GBM) treatment. BEA-17 is a targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST, both of which are implicated in the emergence of various cancers, including GBM. The mechanism of BEA-17 involves the degradation of LSD1 and CoREST, eventually leading to the re-ignition of tumor suppressor genes and the prevention of cancer cell proliferation.

Who Are The Primary Market Leaders In The Adult Malignant Glioma Therapeutics Market?

Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan PLC, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

How Do Regional Dynamics Influence The Adult Malignant Glioma Therapeutics Market Performance?

North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=13178&type=smp

Browse Through More Reports Similar to the Global Adult Malignant Glioma Therapeutics Market 2025, By The Business Research Company

Digital Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/digital-therapeutics-global-market-report

Leukemia Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Liver Diseases Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-diseases-therapeutics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model